


LEGEND-T2DM Evidence Dissemination Summary

Target: **dulaglutide**, Comparator: **dapagliflozin** Outcome: **Venous thromboembolic events**

How Often? (Incidence rates in the PS-matched target cohorts)

Data source	Persons exposed	Person-time (yrs)	Persons with outcome	IR (/1,000 PY)
IQVIA DA Germany	-	-	-	-
IQVIA LDP France	-	-	-	-
IQVIA Open Claims	155,224	121,291	478	3.94
Merative CCAE	10,940	8,925	45	5.04
Merative MDCCD	2,425	1,393	10	7.18
Merative MDCR	1,081	703	10	14.22
Optum Clinformatics	11,689	7,941	58	7.30
Optum EHR	13,556	6,757	43	6.36
Veterans Affairs	-	-	-	-

How Reliable Are the Effect Estimates? (Objective diagnostics)



What have we learned from the OHDSI Network? (Meta-analysis diagnostics and estimate)

